Relapse in the skull after myeloablative therapy for high-risk neuroblastoma

D. Sangthawan, P. M. DesRosiers, M. E. Randall, Kent Robertson, W. Goebel, Robert Fallon

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Patterns of relapse were determined for 20 high-risk neuroblastoma patients treated with chemotherapy, surgery, primary and metastatic site radiation (21 Gray), myeloablative chemotherapy, peripheral blood stem cell rescue, and 13-cis-retinoic acid. The median follow-up duration after transplant is 21 months (range, 8-34 months). The event-free survival and overall survival at 2 years were 45 and 75 %, respectively. There were 2 primary site recurrences. Metastatic sites that became MIBG-scan negative on induction chemotherapy were not irradiated. Four patients relapsed in irradiated metastatic sites, 3 in the skull, 1 in the liver. Failure also occurred at 2 skull sites treated with chemotherapy only, and at 5 new sites: 1 skull, 2 distant lymph nodes, and 2 bones other than skull. Eight of 20 patients had skull metastasis at presentation; 6 were irradiated and 3 were controlled. Skull metastasis warrants more aggressive evaluation and treatment.

Original languageEnglish
Pages (from-to)23-30
Number of pages8
JournalPediatric Hematology and Oncology
Volume20
Issue number1
StatePublished - Jan 2003

Fingerprint

Chemotherapy
Neuroblastoma
Skull
Recurrence
Drug Therapy
Transplants
Therapeutics
Stem cells
Liver
Surgery
3-Iodobenzylguanidine
Neoplasm Metastasis
Isotretinoin
Bone
Induction Chemotherapy
Blood
Radiation
Disease-Free Survival
Acids
Relapse

Keywords

  • Neuroblastoma
  • Radiation
  • Stem cell transplantation

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology
  • Cancer Research
  • Management of Technology and Innovation

Cite this

Relapse in the skull after myeloablative therapy for high-risk neuroblastoma. / Sangthawan, D.; DesRosiers, P. M.; Randall, M. E.; Robertson, Kent; Goebel, W.; Fallon, Robert.

In: Pediatric Hematology and Oncology, Vol. 20, No. 1, 01.2003, p. 23-30.

Research output: Contribution to journalArticle

Sangthawan, D, DesRosiers, PM, Randall, ME, Robertson, K, Goebel, W & Fallon, R 2003, 'Relapse in the skull after myeloablative therapy for high-risk neuroblastoma', Pediatric Hematology and Oncology, vol. 20, no. 1, pp. 23-30.
Sangthawan, D. ; DesRosiers, P. M. ; Randall, M. E. ; Robertson, Kent ; Goebel, W. ; Fallon, Robert. / Relapse in the skull after myeloablative therapy for high-risk neuroblastoma. In: Pediatric Hematology and Oncology. 2003 ; Vol. 20, No. 1. pp. 23-30.
@article{07578dd31d504495809d4fdfa8c5ae34,
title = "Relapse in the skull after myeloablative therapy for high-risk neuroblastoma",
abstract = "Patterns of relapse were determined for 20 high-risk neuroblastoma patients treated with chemotherapy, surgery, primary and metastatic site radiation (21 Gray), myeloablative chemotherapy, peripheral blood stem cell rescue, and 13-cis-retinoic acid. The median follow-up duration after transplant is 21 months (range, 8-34 months). The event-free survival and overall survival at 2 years were 45 and 75 {\%}, respectively. There were 2 primary site recurrences. Metastatic sites that became MIBG-scan negative on induction chemotherapy were not irradiated. Four patients relapsed in irradiated metastatic sites, 3 in the skull, 1 in the liver. Failure also occurred at 2 skull sites treated with chemotherapy only, and at 5 new sites: 1 skull, 2 distant lymph nodes, and 2 bones other than skull. Eight of 20 patients had skull metastasis at presentation; 6 were irradiated and 3 were controlled. Skull metastasis warrants more aggressive evaluation and treatment.",
keywords = "Neuroblastoma, Radiation, Stem cell transplantation",
author = "D. Sangthawan and DesRosiers, {P. M.} and Randall, {M. E.} and Kent Robertson and W. Goebel and Robert Fallon",
year = "2003",
month = "1",
language = "English",
volume = "20",
pages = "23--30",
journal = "Pediatric Hematology and Oncology",
issn = "0888-0018",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Relapse in the skull after myeloablative therapy for high-risk neuroblastoma

AU - Sangthawan, D.

AU - DesRosiers, P. M.

AU - Randall, M. E.

AU - Robertson, Kent

AU - Goebel, W.

AU - Fallon, Robert

PY - 2003/1

Y1 - 2003/1

N2 - Patterns of relapse were determined for 20 high-risk neuroblastoma patients treated with chemotherapy, surgery, primary and metastatic site radiation (21 Gray), myeloablative chemotherapy, peripheral blood stem cell rescue, and 13-cis-retinoic acid. The median follow-up duration after transplant is 21 months (range, 8-34 months). The event-free survival and overall survival at 2 years were 45 and 75 %, respectively. There were 2 primary site recurrences. Metastatic sites that became MIBG-scan negative on induction chemotherapy were not irradiated. Four patients relapsed in irradiated metastatic sites, 3 in the skull, 1 in the liver. Failure also occurred at 2 skull sites treated with chemotherapy only, and at 5 new sites: 1 skull, 2 distant lymph nodes, and 2 bones other than skull. Eight of 20 patients had skull metastasis at presentation; 6 were irradiated and 3 were controlled. Skull metastasis warrants more aggressive evaluation and treatment.

AB - Patterns of relapse were determined for 20 high-risk neuroblastoma patients treated with chemotherapy, surgery, primary and metastatic site radiation (21 Gray), myeloablative chemotherapy, peripheral blood stem cell rescue, and 13-cis-retinoic acid. The median follow-up duration after transplant is 21 months (range, 8-34 months). The event-free survival and overall survival at 2 years were 45 and 75 %, respectively. There were 2 primary site recurrences. Metastatic sites that became MIBG-scan negative on induction chemotherapy were not irradiated. Four patients relapsed in irradiated metastatic sites, 3 in the skull, 1 in the liver. Failure also occurred at 2 skull sites treated with chemotherapy only, and at 5 new sites: 1 skull, 2 distant lymph nodes, and 2 bones other than skull. Eight of 20 patients had skull metastasis at presentation; 6 were irradiated and 3 were controlled. Skull metastasis warrants more aggressive evaluation and treatment.

KW - Neuroblastoma

KW - Radiation

KW - Stem cell transplantation

UR - http://www.scopus.com/inward/record.url?scp=0037215871&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037215871&partnerID=8YFLogxK

M3 - Article

C2 - 12687750

AN - SCOPUS:0037215871

VL - 20

SP - 23

EP - 30

JO - Pediatric Hematology and Oncology

JF - Pediatric Hematology and Oncology

SN - 0888-0018

IS - 1

ER -